Likewise, SIRT1 is recruited to the promoter of E-cadherin and acts as a co-suppressor with ZEB1 to synergistically inhibit E-cadherin transcription, thus promoting EMT in prostate cancer [21]. Here, SIRT1 is linked to prostate carcinoma.